Journal Publication

Trispecific CD19/20/22 CAR T shows 50% response rate in first-in-human trial

Sixteen patients with relapsed or refractory B-cell malignancies received the point-of-care manufactured trispecific CAR T, designed to blunt single-antigen escape that drives relapse after CD19-only CAR T.

By AppliedXLJuly 14, 2026

Executive Summary

A trispecific CAR T cell built to hit three B-cell antigens at once produced responses in half of a small first-in-human cohort, with no cases of severe cytokine release syndrome or neurotoxicity.
The design directly targets the mechanism most often blamed for CAR T relapse: loss or reduced coverage of the single antigen a conventional construct depends on.
Complete responses concentrated heavily among the lymphoma patients who responded, and remissions in that group held over time rather than fading quickly.
A cellular exhaustion marker measured before infusion tracked with which patients progressed, pointing to a manufacturing-stage predictor of failure rather than a dosing problem.

The stake

Relapse after CD19-directed CAR T therapy is common, and antigen loss, reduced antigen density, or incomplete antigen coverage on the tumor cell surface are established drivers of that failure. Widening the target from one antigen to three, CD19, CD20, and CD22, is a direct response to that failure mode: if a tumor cell downregulates or loses one target, the CAR T can still engage through the other two. The construct also carries an OX40 co-stimulatory domain, intended to support persistence and activation of the engineered T cells. Safety

How it was done

Investigators first tested the trispecific CAR construct in vitro and in animal lymphoma models, reporting cytotoxicity that was specific to cells expressing the target antigens. They then moved into a Phase 1 first-in-human trial enrolling patients with relapsed or refractory B-cell malignancies. Sixteen patients received point-of-care manufactured cell infusions, with a median time from apheresis to infusion (vein-to-vein time) of 7 days, at doses ranging from 0.5 to 2x10^6 cells per kilogram. Safety

The results

No patient experienced severe cytokine release syndrome or neurotoxicity, the two toxicities most closely watched in CAR T therapy. The overall response rate across the cohort was 50%, and among the lymphoma patients who responded, 83% achieved complete responses, with durable remissions reported in that group. One-year overall survival across the cohort was 61%. CAR T cell expansion in the blood did not correlate with the dose infused or with whether a patient responded, an early signal that potency in this construct may not scale simply with cell dose. Safety

The resistance signal

T-cell exhaustion measured in the cells collected during apheresis, before manufacturing, correlated with disease progression after infusion. That finding points to the starting material, not the target selection or the dose, as a variable worth tracking: patients whose own T cells were already more exhausted at collection were the ones more likely to progress. It is a mechanistic association reported in the trial's own data, not an established causal driver of relapse. Safety

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.